CHEBI:10454 - cis-flupenthixol

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name cis-flupenthixol
ChEBI ID CHEBI:10454
ChEBI ASCII Name cis-flupenthixol
Definition A flupenthixol in which the double bond adopts a cis-configuration.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Formula C23H25F3N2OS
Net Charge 0
Average Mass 434.520
Monoisotopic Mass 434.16397
InChI InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-
InChIKey NJMYODHXAKYRHW-DVZOWYKESA-N
SMILES OCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): dopaminergic antagonist
A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
(via flupenthixol )
alpha-adrenergic antagonist
An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
(via flupenthixol )
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).
(via flupenthixol )
Application(s): dopaminergic antagonist
A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
(via flupenthixol )
alpha-adrenergic antagonist
An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
(via flupenthixol )
anxiolytic drug
Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
(via flupenthixol )
antidepressant
Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
(via flupenthixol )
first generation antipsychotic
Antipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased.
(via flupenthixol )
View more via ChEBI Ontology
ChEBI Ontology
Outgoing cis-flupenthixol (CHEBI:10454) has role dopaminergic antagonist (CHEBI:48561)
cis-flupenthixol (CHEBI:10454) is a flupenthixol (CHEBI:5121)
cis-flupenthixol (CHEBI:10454) is conjugate base of cis-flupenthixol(2+) (CHEBI:180488)
Incoming cis-flupenthixol(2+) (CHEBI:180488) is conjugate acid of cis-flupenthixol (CHEBI:10454)
IUPAC Name
2-(4-{(3Z)-3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethanol
Synonyms Sources
(Z)-flupenthixol ChEBI
2-(4-{(3Z)-3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol IUPAC
cis-(Z)-flupenthixol KEGG COMPOUND
Manual Xref Database
C11191 KEGG COMPOUND
View more database links
Registry Number Type Source
53772-82-0 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
10320779 PubMed citation Europe PMC
11080543 PubMed citation Europe PMC
17277934 PubMed citation Europe PMC
2054609 PubMed citation Europe PMC
22926199 PubMed citation Europe PMC
24012795 PubMed citation Europe PMC
24134630 PubMed citation Europe PMC
3298419 PubMed citation Europe PMC
3359281 PubMed citation Europe PMC
3439426 PubMed citation Europe PMC
3828778 PubMed citation Europe PMC
3927361 PubMed citation Europe PMC
569233 PubMed citation Europe PMC
6684429 PubMed citation Europe PMC
6889662 PubMed citation Europe PMC
8278431 PubMed citation Europe PMC
Last Modified
20 September 2021